



Express Mail No.: EV452775594US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mohiuddin et al.

U.S. Patent No.: 5,070,877

Application Serial No.: 07/330,156

Issued: December 10, 1991

Filed: May 29, 1989

For: NOVEL METHOD OF MYOCARDIAL
IMAGING

Attorney Docket No: 11201-512-999
(Formerly: 57459(46453))

TRANSMITTAL OF REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 2233-1450

Sir:

Pursuant to 37 C.F.R. § 1.36, Applicants submit herewith a Revocation and Power of Attorney executed by M. King Jolly, Executive Vice President of King Pharmaceuticals Research & Development, Inc, the assignee of the entire right, title and interest in, to and under the above-identified application.

Please direct all correspondence and telephone calls to Jones Day at the address indicated below. It is estimated that no fee is due in connection with this transmittal. In the event that a fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

by *Jaqueline Benn*
Reg No. 43,492
Thomas G. Rowan

34,419

Date: June 30, 2005

Thomas G. Rowan (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-39390

Enclosure



7-5-05

DSD

Express Mail No.: EV452775594US

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COMPLETED

Application of: Mohiuddin et al.

U.S. Patent No.: 5,070,877

Application Serial No.: 07/330,156

Issued: December 10, 1991

Filed: May 29, 1989

For: NOVEL METHOD OF MYOCARDIAL IMAGING

Attorney Docket No.: 11201-512-999
Formerly: 57459-CIP(46453)**REVOCATION AND POWER OF ATTORNEY**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

King Pharmaceuticals Research & Development, Inc. hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number 20583

as his/her/its/their attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.


Please direct all correspondence address for the above-identified application to:

☒ The above mentioned Customer Number.☒ Firm or Individual Name:Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

- ☐
- Applicant/Inventor
-
- ☒
- Assignee of record of the entire interest. See 37 CFR 3.71.
-
- (Statement under 37 CFR 3.73(b) is applicable)

SIGNATURE of Applicant or Assignee of Record			
Date:		Signature:	
		Typed Name:	M. King Jolly, Pharm.D.
		Position/Title:	Executive Vice President

Statement Under 37 C.F.R. 3.73(b)

King Pharmaceuticals Research & Development, Inc. states that it is:

- ☒
- the assignee of the entire right, title, and interest; or
-
- ☐
- an assignee of less than the entire right, title and interest.

The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of either:

- ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office on April 20, 1989 at Reel 5080, Frame 0686.

OR

- ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Syed M. Mohiuddin and Daniel E. Hilleman To: Medco Research, Inc. The document was recorded in the United States Patent and Trademark Office on April 20, 1989 at Reel 005080, Frame 0686.

2. From: Medco Research Inc. To: King Pharmaceuticals Research & Development, Inc. The document was recorded in the United States Patent and Trademark Office on April 30, 2001 at Reel 011751, Frame 0195.


3. From: Medco Research, Inc. To: King Pharmaceuticals Research and Development, Inc. The document was recorded in the United States Patent and Trademark Office on May 22, 2001 at Reel 011828, Frame 0668.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: King Pharmaceuticals Research & Development, Inc.

Date: _____ Signature: 
Typed Name: M. King Jolly, Pharm.D.
Position/Title: Executive Vice President

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

- ☐ Total of _____ forms are submitted.